Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials

Fred Yang,1 June Ye,2 Kenneth Pomerantz,3 Murray Stewart1 1Alternative Development Program, GlaxoSmithKline, King of Prussia, PA, 2Discovery Biometrics, GlaxoSmithKline, Research Triangle Park, NC, 3Clinical Development and Medical Affairs, Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yang F, Ye J, Pomerantz K, Stewart M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://doaj.org/article/912265badf8e4dbb897f67b8f1ac6522
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!